May 25, 2017
Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics
Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising $45 million.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
May 25, 2017
FDA OK’s Roche’s arteritis drug
The U.S. Food and Drug Administration (FDA) has approved Roche’s Actemra/RoActemra (tocilizumab) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition.
May 24, 2017
FDA Advisory Committee recommends approval of Emmaus Life Sciences’s sickle cell disease drug
The Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of Emmaus Life Sciences’s Endari for the treatment of sickle cell disease (SCD) is favorable.
May 24, 2017
Bioverativ buys San Francisco-based True North Therapeutics
Bioverativ has acquired South San Francisco-based True North Therapeutics, a privately-held, clinical-stage rare disease biotechnology company, for an upfront payment of $400 million plus assumed cash.
May 24, 2017
Kristin Chenoweth kicks off Allergan’s skin disease awareness campaign
Emmy and Tony award-winning actress and singer, Kristin Chenoweth will kick off Allergan’s “Less Red, More You” campaign at an exclusive event in New York City.
May 23, 2017
Boehringer Ingelheim’s asthma drug test shows good results
Boehringer Ingelheim has reported new analyses that provide further evidence that adding SPIRIVA RESPIMAT improved breathing across diverse patient populations who experience uncontrolled asthma symptoms despite the use of another daily maintenance therapy in the Phase III clinical development program.
May 23, 2017
Alexion Pharmaceuticals welcomes new CCO, makes other managerial changes
Alexion Pharmaceuticals has announced big changes to its executive leadership team. Brian Goff is joining Alexion as Chief Commercial Officer, effective June 1, 2017.
May 23, 2017
Sanofi and Regeneron win FDA approval for its rheumatoid arthritis drug
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).
May 23, 2017
Novo Nordisk submits application in the US for label addition for its diabetes drug
Novo Nordisk has submitted a supplemental application to the US Food and Drug Administration (FDA) for including data in the label for Tresiba (insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes.
May 19, 2017
FDA expands Kalydeco indication for cystic fibrosis
The U.S. Food and Drug Administration (FDA) expanded the approved indication for Vertex Pharmaceuticals’ Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF).